High Insider Ownership Growth Stocks On The German Exchange In June 2024

As of June 2024, the German market has shown resilience, with the DAX index posting modest gains amid broader European economic adjustments and interest rate cuts by the ECB. This backdrop creates a nuanced environment for investors looking at growth companies with high insider ownership, which are often well-positioned to navigate shifting economic landscapes due to aligned interests between management and shareholders.

Top 10 Growth Companies With High Insider Ownership In Germany

Name	Insider Ownership	Earnings Growth
pferdewetten.de (XTRA:EMH)	26.8%	75.4%
Deutsche Beteiligungs (XTRA:DBAN)	35.4%	31.6%
YOC (XTRA:YOC)	24.8%	22.2%
NAGA Group (XTRA:N4G)	14.1%	58.1%
Exasol (XTRA:EXL)	25.3%	107.4%
Alelion Energy Systems (DB:2FZ)	37.4%	106.6%
Stratec (XTRA:SBS)	30.9%	22%
Redcare Pharmacy (XTRA:RDC)	17.7%	46.9%
Your Family Entertainment (DB:RTV)	17.5%	116.8%
Friedrich Vorwerk Group (XTRA:VH2)	18%	30.4%

Click here to see the full list of 18 stocks from our Fast Growing German Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Brockhaus Technologies

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Brockhaus Technologies AG operates as a private equity firm with a market capitalization of approximately €307.16 million.

Operations: The company's revenue is primarily generated from its Financial Technologies and Security Technologies segments, contributing €153.43 million and €39.43 million respectively.

Insider Ownership: 26.6%

Earnings Growth Forecast: 74.2% p.a.

Brockhaus Technologies AG, a growth-oriented company with significant insider ownership, has demonstrated robust revenue growth and ambitious future targets. Despite recent financial results showing a net loss—EUR 1.38 million in Q1 2024 and EUR 3.34 million for the full year 2023—the company is optimistic, projecting revenues between EUR 220 million and EUR 240 million for 2024, indicating potential strong organic growth. Furthermore, Brockhaus has initiated its first-ever dividend at EUR 0.22 per share, underscoring confidence in its financial health and commitment to shareholder value amidst challenging conditions.

• Navigate through the intricacies of Brockhaus Technologies with our comprehensive analyst estimates report here.

• According our valuation report, there's an indication that Brockhaus Technologies' share price might be on the cheaper side.

XTRA:BKHT Ownership Breakdown as at Jun 2024

Deutsche Beteiligungs

Simply Wall St Growth Rating: ★★★★★☆

Overview: Deutsche Beteiligungs AG is a private equity and venture capital firm that specializes in direct and fund of funds investments, with a market capitalization of approximately €523.16 million.

Operations: The company generates revenue primarily through two segments: Fund Investment Services, which contributes €47.85 million, and Private Equity Investments, accounting for €55.15 million.

Insider Ownership: 35.4%

Earnings Growth Forecast: 31.6% p.a.

Deutsche Beteiligungs AG, with high insider ownership, is poised for substantial growth. Analysts predict a significant rise in earnings by 31.6% annually over the next three years, outpacing the German market's 18.6%. Revenue is also expected to grow robustly at 24.7% annually. Despite a low forecasted Return on Equity of 17.5%, the recent share buyback program underscores strong confidence in future value, enhancing shareholder returns through strategic repurchases valued at €25 million until February 2025.

• Click here to discover the nuances of Deutsche Beteiligungs with our detailed analytical future growth report.

• The valuation report we've compiled suggests that Deutsche Beteiligungs' current price could be quite moderate.

XTRA:DBAN Earnings and Revenue Growth as at Jun 2024

Redcare Pharmacy

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Redcare Pharmacy NV is a company that operates an online pharmacy business across the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France, with a market capitalization of approximately €2.40 billion.

Operations: The company generates revenue primarily through its DACH region segment, which brought in €1.62 billion, and its International segment, contributing €0.37 billion.

Insider Ownership: 17.7%

Earnings Growth Forecast: 46.9% p.a.

Redcare Pharmacy, trading at 40.8% below its estimated fair value, is forecasted to become profitable within the next three years, aligning with an anticipated revenue growth of 17% per year—outpacing the German market's 5.2%. Despite recent earnings showing a reduction in net loss from €10.22 million to €7.81 million and a significant sales increase to €560.22 million, shareholders have experienced dilution over the past year, and the stock has shown high volatility in recent months.

• Dive into the specifics of Redcare Pharmacy here with our thorough growth forecast report.

• Our valuation report unveils the possibility Redcare Pharmacy's shares may be trading at a premium.

XTRA:RDC Ownership Breakdown as at Jun 2024

Taking Advantage

• Discover the full array of 18 Fast Growing German Companies With High Insider Ownership right here.

• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.

• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include XTRA:BKHTXTRA:DBANXTRA:RDC and

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com